Pacira BioSciences Inc (PCRX)
26.48
-0.73
(-2.68%)
USD |
NASDAQ |
May 06, 16:00
26.53
+0.05
(+0.19%)
After-Hours: 20:00
Pacira BioSciences Cash from Financing (TTM): -183.03M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -183.03M |
| September 30, 2023 | -239.76M |
| June 30, 2023 | -219.75M |
| March 31, 2023 | -373.85M |
| December 31, 2022 | -401.53M |
| September 30, 2022 | 18.39M |
| June 30, 2022 | 29.22M |
| March 31, 2022 | 188.78M |
| December 31, 2021 | 380.69M |
| September 30, 2021 | 29.65M |
| June 30, 2021 | 236.35M |
| March 31, 2021 | 233.91M |
| December 31, 2020 | 222.30M |
| September 30, 2020 | 209.92M |
| June 30, 2020 | 1.586M |
| March 31, 2020 | 1.859M |
| December 31, 2019 | 3.67M |
| September 30, 2019 | 9.218M |
| June 30, 2019 | 10.78M |
| March 31, 2019 | 9.065M |
| December 31, 2018 | 8.954M |
| September 30, 2018 | 7.706M |
| June 30, 2018 | 7.412M |
| March 31, 2018 | 7.725M |
| December 31, 2017 | 224.16M |
| Date | Value |
|---|---|
| September 30, 2017 | 222.95M |
| June 30, 2017 | 221.03M |
| March 31, 2017 | 221.08M |
| December 31, 2016 | 7.261M |
| September 30, 2016 | 8.363M |
| June 30, 2016 | 9.417M |
| March 31, 2016 | 9.693M |
| December 31, 2015 | 10.70M |
| September 30, 2015 | 11.26M |
| June 30, 2015 | 11.82M |
| March 31, 2015 | 120.96M |
| December 31, 2014 | 118.88M |
| September 30, 2014 | 116.95M |
| June 30, 2014 | 115.55M |
| March 31, 2014 | 4.943M |
| December 31, 2013 | 89.16M |
| September 30, 2013 | 88.59M |
| June 30, 2013 | 87.86M |
| March 31, 2013 | 150.68M |
| December 31, 2012 | 63.61M |
| September 30, 2012 | 112.50M |
| June 30, 2012 | 112.26M |
| March 31, 2012 | 48.26M |
| December 31, 2011 | 87.16M |
| September 30, 2011 | 59.10M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-401.53M
Minimum
Dec 2022
380.69M
Maximum
Dec 2021
8.338M
Average
10.78M
Median
Jun 2019
Cash from Financing (TTM) Benchmarks
| Dynavax Technologies Corp | 1.386M |
| Arbutus Biopharma Corp | 34.66M |
| Chimerix Inc | 0.317M |
| Karyopharm Therapeutics Inc | 1.124M |
| FibroGen Inc | 122.75M |